Navigation Links
Shining light on neurodegenerative pathway
Date:9/18/2013

University of Adelaide researchers have identified a likely molecular pathway that causes a group of untreatable neurodegenerative diseases, including Huntington's disease and Lou Gehrig's disease.

The group of about 20 diseases, which show overlapping symptoms that typically include nerve cell death, share a similar genetic mutation mechanism ‒ but how this form of mutation causes these diseases has remained a mystery.

"Despite the genes for some of these diseases having been identified 20 years ago, we still haven't understood the underlying mechanisms that lead to people developing clinical symptoms," says Professor Robert Richards, Head of Genetics in the University's School of Molecular and Biomedical Sciences.

"By uncovering the molecular pathway for these diseases, we now expect to be able to define targets for intervention and so come up with potential therapies. Ultimately this will help sufferers to reduce the amount of nerve cell degeneration or slow its progression."

In an article published in Frontiers in Molecular Neuroscience, Professor Richards and colleagues describe their innovative theory and new evidence for the key role of RNA in the development of the diseases. RNA is a large molecule in the cell that copies genetic code from the cell's DNA and translates it into the proteins that drive biological functions.

People with these diseases all have expanded numbers of copies of particular sequences of the 'nucleotide bases' which make up DNA.

"In most cases people with these diseases have increased numbers of repeat sequences in their RNA," says Professor Richards. "The disease develops when people have too many copies of the repeat sequence. Above a certain threshold, the more copies they have the earlier the disease develops and the more severe the symptoms. The current gap in knowledge is why having these expanded repeat sequences of genes in the RNA translates into actual
'/>"/>

Contact: Robert Richards
robert.richards@adelaide.edu.au
61-422-007-867
University of Adelaide
Source:Eurekalert

Page: 1 2

Related biology news :

1. Recent highlights in Molecular Biology and Evolution
2. Lab-on-a-chip tech, brain mapping & microbiome highlighted at translational med meeting
3. Research highlights from ICAAC meeting
4. Survey highlights barriers to interdisciplinary environmental science
5. Rutgers study: Worms may shed light on human ability to handle chronic stress
6. AGU journal highlights -- Aug. 13, 2013
7. Family matters: Evolutionary relationships among species of magic mushrooms shed light on fungi
8. Montana State University researchers highlight bears use of Banff highway crossings
9. Light that moves and molds gels
10. Study highlights possible new approach to prostate cancer treatment
11. Controlling genes with light
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 26, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... a new corporate website ( http://www.nxt-id.com/ ) as part ... Wocket™ smart wallet. The Company launched its new consumer ... Gino Pereira , CEO of NXT-ID said, "Our ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... drinking water in Bangladesh called the "largest mass ... Health Organization and known to be responsible for a ... to have an immediate and toxic effect on the ... is the first to identify a dramatic present-day consequence ...
... HARBOR, N.Y. (Nov. 30, 2010) -- The nucleus of ... DNA replication, transcription, and RNA processing take place. Within the ... according to the functional demands of the cell. "The ... is arguably one of the most exciting fields of contemporary ...
... For Immediate Release A team of scientists from The ... in the body,s response to eliminate pathogens, such as bacteria ... field of immunology and have potential implications for far-ranging topics ... autoimmunity. The results of the study, led by Scripps ...
Cached Biology News:Arsenic-polluted water toxic to Bangladesh economy 2Arsenic-polluted water toxic to Bangladesh economy 3Arsenic-polluted water toxic to Bangladesh economy 4Scripps Research scientists redefine the role of plasma cells in the immune system 2Scripps Research scientists redefine the role of plasma cells in the immune system 3Scripps Research scientists redefine the role of plasma cells in the immune system 4
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading personal ... Black as Privacy Officer and Corporate Counsel. Black ... privacy laws as well as health care regulations. As ... will be responsible for reviewing, updating and enhancing the ... U.S. and abroad. She joined the company January 5, ...
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... FRAMINGHAM, Mass. and SYDNEY, Nov. 18, 2010 HeartWare ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that CEO Doug Godshall is scheduled ... Piper Jaffray Health Care Conference on Tuesday, November 30, ...
... Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
... Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
Cached Biology Technology:HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 2Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 3Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 4Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 5Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 6Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 7Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 8Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 9Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors 10Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 2Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 3Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 4Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 5Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 6Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 7Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 8Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 9Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 10Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 11
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: polystyrene flat ...
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... for in vitro diagnostic assays, all EIA/RIA ... for uniform binding, high optical clarity and ... are part of the Certified Surface Chemistry ... be within QA release specifications. Linkage: This ...
... clarification reagent; Ideal for clarifying many ... proteins, nucleic acids, & proteoglycans; Contains ... improves downstream processing; Utilizes a reagent ... supplied as a suspension in saline; ...
Biology Products: